Clinical and research tests for C0345893 - Genetic Testing Registry (GTR) - NCBI

Warning: The NCBI web site requires JavaScript to function. more...

<< First< Prev

Page 1 of 4

Results: 1 to 20 of 68

Tests names and labs	Conditions	Genes, analytes, and microbes	Methods
Expedio Hereditary Cancer Predisposition Screening Assay Kailos Genetics United States	40	31	C Sequence analysis of the entire coding region
Otogenetics Hereditary Cancers Otogenetics United States	36	39	E Sequence analysis of select exons
Common Hereditary Cancer Screening Panel PreventionGenetics United States	94	55	D Deletion/duplication analysis C Sequence analysis of the entire coding region T Targeted variant analysis
myRisk Hereditary Cancer Myriad Genetics, Inc. United States	32	46	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Blood Coagulation Panel Centogene US, LLC - The Rare Disease Company United States	110	112	D Deletion/duplication analysis C Sequence analysis of the entire coding region T Targeted variant analysis
CentoDysmorph Panel Centogene US, LLC - The Rare Disease Company United States	740	728	D Deletion/duplication analysis C Sequence analysis of the entire coding region
CentoHear Panel Centogene US, LLC - The Rare Disease Company United States	203	194	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Connective Tissue and Related Disorder Panel Centogene US, LLC - The Rare Disease Company United States	75	76	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Pancreatitis Panel Centogene US, LLC - The Rare Disease Company United States	27	29	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Pulmonary Panel Centogene US, LLC - The Rare Disease Company United States	99	101	D Deletion/duplication analysis C Sequence analysis of the entire coding region T Targeted variant analysis
CentoNeuro Panel Centogene US, LLC - The Rare Disease Company United States	1886	1858	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Intellectual Disability Panel Centogene US, LLC - The Rare Disease Company United States	777	770	D Deletion/duplication analysis C Sequence analysis of the entire coding region T Targeted variant analysis
SMAD4 - MLPA Centogene US, LLC - The Rare Disease Company United States	4	1	D Deletion/duplication analysis
CentoColon Centogene US, LLC - The Rare Disease Company United States	67	33	D Deletion/duplication analysis C Sequence analysis of the entire coding region
CentoCancer Centogene US, LLC - The Rare Disease Company United States	114	68	D Deletion/duplication analysis C Sequence analysis of the entire coding region
CentoCancer Comprehensive Centogene US, LLC - The Rare Disease Company United States	156	107	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Solid Tumor Panel Centogene US, LLC - The Rare Disease Company United States	218	135	C Sequence analysis of the entire coding region
SMAD4 - NGS including CNV analysis Centogene US, LLC - The Rare Disease Company United States	4	1	D Deletion/duplication analysis C Sequence analysis of the entire coding region
CentoColon Centogene AG - the Rare Disease Company Germany	67	33	D Deletion/duplication analysis C Sequence analysis of the entire coding region
CentoCancer Centogene AG - the Rare Disease Company Germany	114	68	D Deletion/duplication analysis C Sequence analysis of the entire coding region

<< First< Prev

Page 1 of 4

Results: 1 to 20 of 68

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.